Charles Schwab Investment Management Inc. Has $204,000 Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Charles Schwab Investment Management Inc. grew its stake in Fractyl Health, Inc. (NASDAQ:GUTS) by 56.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 80,664 shares of the company’s stock after purchasing an additional 29,262 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.17% of Fractyl Health worth $204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of GUTS. Rhumbline Advisers bought a new stake in Fractyl Health in the second quarter valued at $32,000. SG Americas Securities LLC acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at $33,000. Renaissance Technologies LLC acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $61,000. Beta Wealth Group Inc. bought a new stake in shares of Fractyl Health in the 3rd quarter worth about $44,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Fractyl Health by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after purchasing an additional 25,829 shares in the last quarter.

Fractyl Health Trading Down 4.2 %

Shares of GUTS stock opened at $1.82 on Friday. The company has a market capitalization of $87.54 million and a P/E ratio of -0.15. Fractyl Health, Inc. has a 12-month low of $1.74 and a 12-month high of $14.50. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average price of $2.38 and a 200 day moving average price of $3.23.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. Research analysts forecast that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Fractyl Health

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $158,566.59. Following the completion of the sale, the insider now owns 153,544 shares in the company, valued at approximately $379,253.68. This trade represents a 29.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the completion of the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. This represents a 16.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.